Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 15, 2009

Ono to Use Evotec’s Ion-Channel Drug Discovery Platform in Expanded Deal

  • Evotec extended and expanded its current research collaboration with Ono Pharmaceutical. The firm will provide additional activities including high-throughput screening, medicinal chemistry, and in vitro pharmacology to find novel, small molecular weight compounds active against an ion channel target selected by Ono. Ono will provide research funding and milestone payments.

    Evotec and Ono have collaborated since March 2008, identifying novel inhibitors for a protease target. Within this collaboration, Evotec provides protein crystallography, medicinal chemistry, biology, and ADMET services to Ono with the aim of progressing a compound toward clinical development. 



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »